Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cutaneous lupus erythematosus15.06.02.007; 10.04.03.007; 23.03.02.0080.000186%Not Available
Pharyngeal erythema22.04.05.0100.000186%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000186%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000373%Not Available
Vascular stenosis24.04.02.020--Not Available
Bipolar disorder19.16.01.003--Not Available
Bloody discharge24.07.01.041; 08.01.03.0390.000280%Not Available
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.000280%Not Available
Pulseless electrical activity02.03.04.0200.000420%Not Available
Hypoperfusion24.06.02.019--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Cerebral vasoconstriction24.04.06.025; 17.08.02.0120.000233%Not Available
Urine output increased13.13.03.002--Not Available
Antinuclear antibody positive13.06.01.003--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Adverse event08.06.01.010--Not Available
Arterial disorder24.03.02.0200.000252%Not Available
Breast disorder21.05.04.004--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000093%Not Available
Foetal disorder18.03.02.0010.000186%Not Available
Infarction24.04.02.017--Not Available
Inflammation10.02.01.089; 08.01.05.0070.000326%Not Available
Ischaemic stroke17.08.01.018; 24.04.06.010--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Mucosal haemorrhage24.07.01.011; 08.01.06.0050.000093%Not Available
Oral neoplasm07.21.08.002; 16.13.09.0020.000326%Not Available
The 19th Page    First    Pre   19 20 21 22 23    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene